


Information

Name	Swiss Allocation Value Equity	Launch date	16.01.2023
Symbol	S A V E BC	Currency	CHF
Valor	122 922 416	Dividend	Accumulating
ISIN	CH1229224162	Investmentmanager	Beck Asset Management
NAV per Share	120.7797	Custodian Bank	Bank Cantonale Vaudoise
Net assets	CHF 4.5 Mio.	Tradeable	Daily
Investment Universe	Equities Switzerland	Total Fees (excl. Trx fees)	1.2% (Issuer and Manager)
Benchmark	SPIEX 75% und SMIC 25%	Performance Fee	10% HWM
Domicile	Switzerland		

Performance

		Jan	Feb	Mär	Apr	Mai	Jun	Jul	Aug	Sep	Okt	Nov	Dez	
2023	SAVE	+0.19%	+1.28%	+3.01%	+0.24%	+1.21%	+2.04%	-0.05%	-3.7%	-3.98%	-5.07%	+6.77%	+3.08%	4.49%
	Benchmark	-0.07%	+0.02%	+0.69%	+2.65%	-1.59%	-0.06%	+2.14%	-2.38%	-3.41%	-5.25%	+6.33%	+2.71%	1.23%
2024	SAVE	-0.85%	+3.28%	+4.01%	-3.26%	+4.46%	-1.43%	+3.53%	+0.72%	-1.04%	-3.45%	+0.22%	-2.27%	3.51%
	Benchmark	+0.51%	+0.50%	+3.34%	-1.83%	+3.83%	-0.92%	+2.57%	+1.01%	-0.07%	-3.74%	-1.15%	-0.97%	2.81%
2025	SAVE	+8.23%	-4.62%	-4.17%	+0.14%	+5.67%	+1.94%	+4.87%	+0.92%	-2.55%	+0.46%	-1.35%	+0.99%	10.68%
	Benchmark	+7.16%	+0.25%	-2.57%	-1.22%	+4.97%	-0.28%	+1.59%	-0.19%	-1.83%	+1.95%	+1.71%	+2.69%	15.00%



Retrospect

AMC closed the 2025 financial year with a performance of **+10.68%**.

The market environment for Swiss small- and mid-cap equities was overall solid in 2025. Despite periods of volatility, the market developed positively, which was reflected accordingly in the annual performance. Trade policy uncertainties weighed on the market at times, particularly in connection with tariffs announced and partially implemented by Donald Trump. These led to increased planning efforts for certain companies and temporary share price declines.

Largest positions in the SAVE Certificate

Galderma (6.88%)

Galderma has been listed on the stock exchange since March 2024 and recorded a share price increase of more than 60% in 2025. The market launch of the drug Nemluvio, which is used to treat various skin conditions, is progressing better than expected.


Holcim (5.34%)

Holcim is consistently pursuing its announced strategic realignment. With the acquisition of **Alkern**, the group is specifically strengthening the high-margin Solutions & Building segment.


Sandoz (4.76%)

Sandoz is successfully focusing on expanding its biosimilar portfolio. In 2025, the company launched, among others, **Wyost** for the treatment of cancer-related bone diseases and **Jubbonti** for osteoporosis therapy.

Top 5 Positions



Allocation by Sector



Investment Focus

We use a fundamental bottom-up approach to identify the most attractive companies and construct a portfolio that is diversified across sectors and styles (value, GARP, growth).

Before being included in the fund portfolio, each company is analyzed according to qualitative and quantitative criteria:

- Generation of sustainably high returns on capital employed (ROCE)
- Generation of high, predictable free cash flow
- High organic growth leading to high ROCEs
- Competitive advantages that are difficult to replicate
- Low economic sensitivity, stable business models
- Solid balance sheet ratios, high innovative strength
- Experienced management with good track record
- Attractive valuation
- Low ESG reputational risks

Disclaimer

Responsible / Author:

The statements and data in this publication have been compiled by BECK ASSET MANAGEMENT AG to the best of its knowledge for informational and marketing purposes only. This publication constitutes neither a solicitation nor an offer or recommendation to buy or sell any investment instruments or to engage in any other transactions. It also does not constitute advice on legal, tax or other matters. The information contained in this publication should not be considered as a personal recommendation and does not consider the investment objectives or strategies or the financial situation or needs of any particular person. It is based on numerous assumptions. Different assumptions may lead to materially different results. All information and opinions contained in this publication have been obtained from sources believed to be reliable and credible. BECK ASSET MANAGEMENT AG and its employees disclaim any liability for incorrect or incomplete information as well as losses or lost profits that may arise from the use of information and the consideration of opinions.

A performance or positive return on an investment is no guarantee for performances and a positive return in the future. Likewise, exchange rate fluctuations may have a negative impact on the performance, value or return of financial instruments. All information and opinions as well as stated forecasts, assessments and market prices are current only at the time of preparation of this publication and may change at any time without notice. Duplication or reproduction of this publication, in whole or in part, is not permitted without the prior written consent of BECK ASSET MANAGEMENT AG is not permitted. Unless otherwise agreed in writing, any distribution and transmission of this publication material to third parties is prohibited. BECK ASSET MANAGEMENT AG accepts no liability for claims or actions by third parties arising from the use or distribution of this publication. The distribution of this publication may only take place within the framework of the legislation applicable to it. It is not intended for individuals abroad who are not permitted access to such publications due to the legal system of their country of domicile.

January, 2026 / Zurich